Estrella Immunopharma, Inc. announced on September 27, 2024, that the first patient enrolled in its STARLIGHT-1 Phase I/II clinical trial achieved a complete response (CR). This milestone occurred one month after the patient received an infusion of EB103 CD19-Redirected ARTEMIS® T Cells.
The STARLIGHT-1 trial is evaluating EB103, a CD19-targeted ARTEMIS® T-cell therapy, for the treatment of cancer and autoimmune diseases. A complete response indicates the disappearance of all signs of cancer in response to treatment.
This early clinical outcome provides initial evidence of the therapeutic potential of EB103. It marks a critical step in the clinical development pathway for Estrella's lead product candidate.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.